Clinical Trial of the Week: Screening study of patients with stage IV or recurrent non-small cell lung cancer

By Donna Loyle, communications specialist, LIMR

Lung-MAP is a master screening protocol for previously treated, non-small cell lung cancer (NSCLC). This randomized phase II/phase III trial is meant to establish a method for screening the genes of large populations of cancer patients and then assigning those patients, when appropriate, to a sub-study. If assigned to a sub-study, participants then undergo a new, targeted cancer therapy or a combination of standard care.

Eligible patients must have been diagnosed with stage IV or recurrent NSCLC, previously undergone at least one line of systemic therapy for any stage of NSCLC, and have progressed during or after their most recent line of therapy.

Lung-MAP contains a screening component and a clinical trial component:

  • Patients can participate in the screening component either at progression on prior therapy or to be pre-screened while receiving therapy.
  • The clinical trial component consists of studies evaluating drug-biomarker combination for patients determined to have a matching biomarker, and non-match studies evaluating therapies in patients without any of the study biomarkers.

Lung-MAP sub-studies available at Main Line Health:

  • 1800A is testing ramucirumab and pembrolizumab vs. standard of care in treating patients with stage IV or recurrent NSCLC.
  • S1900A is a phase II study of rucaparib in patients with genomic LOH high and/or deleterious BRCA 1/2 mutation stage IV or recurrent NSCLC.

Contact the clinical trials team for additional details on sub-study eligibility.

Lung-MAP is approved for all Main Line Health acute care hospitals. The principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. For more, email cancertrials@mlhs.org or visit https://www.mainlinehealth.org/research/clinical-trials/lung-map.

This entry was posted in Clinician News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *